Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402532 | 0.89 | HTR2C (0.52) | HTR2CCNR1 | |
| SCHEMBL3400023 | 0.87 | HTR2C (0.73) | HTR2CCNR1PARP1 | |
| SCHEMBL3400469 | 0.85 | HTR2C (0.56) | HTR2CCNR1 | |
| SCHEMBL3405516 | 0.85 | HTR2C (0.53) | HTR2CCNR1HRH3PDK2 | |
| SCHEMBL3399878 | 0.85 | HTR2C (0.58) | HTR2CCNR1HRH3PARP1PDK2 | |
| SCHEMBL3402583 | 0.85 | HTR2C (0.53) | HTR2CCNR1HRH3PARP1PDK2 | |
| SCHEMBL3403464 | 0.84 | HTR2C (0.52) | HTR2CCNR1HRH3PARP1PDK2 | |
| SCHEMBL3399761 | 0.81 | HTR2C (0.53) | HTR2CCNR1 | |
| SCHEMBL3405381 | 0.80 | HTR2C (0.60) | HTR2CHRH3 | |
| SCHEMBL3400898 | 0.80 | HTR2C (0.60) | HTR2CHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006089076-A9 | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | HTR2C 416/4885CNR1 35/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.